公开(公告)号：US20220213092A1

公开(公告)日：2022-07-07

申请号：US17552396

申请日：2021-12-16

Applicant: AbbVie Inc.

Inventor： David A. DeGoey ,  Felix DeAnda, Jr. ,  Amanda W. Dombrowski ,  Igor Dubovyk ,  Stephen N. Greszler ,  Dimitri Khrakovsky ,  Chih-Hung Lee ,  James N. Newton ,  Elizabeth L. Noey ,  Akinori Okano ,  Kevin B. Sippy ,  Andrew J. Souers ,  Longcheng Wang ,  Noel S. Wilson ,  Jeffery A. Zablocki

IPC: C07D471/04 ,  C07D519/00 ,  C07D487/04

Abstract: The present invention provides for compounds of formula (I) wherein A, R1, R2, R4, W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.

公开(公告)号：US20160022658A1

公开(公告)日：2016-01-28

申请号：US14877783

申请日：2015-10-07

Applicant: AbbVie Inc.

Inventor： Murali Gopalakrishnan ,  Marie P. Honore ,  Chih-Hung Lee ,  John Malysz ,  Jianguo Ji ,  Tao Li ,  Michael R. Schrimpf ,  Kevin B. Sippy ,  David J. Anderson

IPC: A61K31/4439 ,  A61K31/444 ,  G01N33/94 ,  C07D413/04 ,  C07D413/14 ,  A61K45/06 ,  A61K31/4427 ,  A61K31/4709

CPC classification number: A61K31/4439 ,  A61K31/4245 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4709 ,  A61K45/06 ,  C07D413/04 ,  C07D413/14 ,  G01N33/944 ,  G01N2333/70571 ,  A61K2300/00

Abstract: The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.

Abstract translation: 本发明涉及包含神经元烟碱性受体配体和α4和bgr2阳性变构调节剂，其使用方法和相关制品的组合物。

公开(公告)号：US20150353550A1

公开(公告)日：2015-12-10

申请号：US14715330

申请日：2015-05-18

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Chih-Hung Lee ,  Tao Li ,  Gregory A. Gfesser ,  Kathleen H. Mortell ,  Ramin Faghih ,  Diana L. Nersesian ,  Kevin B. Sippy ,  William H. Bunnelle ,  Marc Scanio ,  Lei Shi ,  Murali Gopalakrishnan ,  Diana L. Donnelly-Roberts ,  Min Hu

IPC: C07D471/18

CPC classification number: G01N33/5058 ,  C07D471/18 ,  C07D487/10 ,  C07D487/18 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/30

Abstract: The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及式（I），（II），（III），（IV），（V）或（VI）的吲哚和二氢吲哚衍生物，其中a，R1，R2，R3，R4，R5， V，W，X，Y和Z如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：US20150158867A1

公开(公告)日：2015-06-11

申请号：US14624517

申请日：2015-02-17

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Diana L. Nersesian ,  Kevin B. Sippy ,  Jianguo Ji ,  Tao Li ,  Marc Scanio ,  Lei Shi ,  Chih-Hung Lee ,  William H. Bunnelle ,  Geoff G.Z. Zhang ,  Paul J. Brackemeyer ,  Shuang Chen ,  Rodger F. Henry

IPC: C07D471/18 ,  A61K31/439 ,  A61K31/501 ,  A61K31/444 ,  C07C309/29 ,  A61K31/095

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Abstract translation: 本发明涉及作为氮杂金刚烷衍生物的化合物，特别是醚取代或胺取代的氮杂金刚烷衍生物及其盐和前体药物，包含这些化合物的组合物，使用这些化合物和组合物的方法，制备这些化合物的方法以及在此过程中获得的中间体 。

公开(公告)号：US08987453B2

公开(公告)日：2015-03-24

申请号：US13653192

申请日：2012-10-16

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Diana L. Nersesian ,  Kevin B. Sippy ,  Jianguo Ji ,  Tao Li ,  Marc Scanio ,  Lei Shi ,  Chih-Hung Lee ,  William H. Bunnelle ,  Geoff G. Z. Zhang ,  Paul J. Brackemeyer ,  Shuang Chen ,  Rodger F. Henry

IPC: C07D471/18 ,  A61K45/06 ,  A61K31/444 ,  C07D471/08 ,  C07F5/02 ,  A61K31/439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Abstract translation: 本发明涉及作为氮杂金刚烷衍生物的化合物，特别是醚取代或胺取代的氮杂金刚烷衍生物及其盐和前体药物，包含这些化合物的组合物，使用这些化合物和组合物的方法，制备这些化合物的方法以及在此过程中获得的中间体 。

公开(公告)号：US20130317056A1

公开(公告)日：2013-11-28

申请号：US13826532

申请日：2013-03-14

Applicant: ABBVIE INC.

Inventor： George M. Haig ,  Jeffrey F. Waring ,  Chih-Hung Lee ,  Deli Wang

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4748 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2800/302

Abstract: This application is directed to a-neuronal nicotinic receptor agonists selective for α7-subtype that are useful for improving cognition impairment in patients having schizophrenia, a schizophreniform disorder or a related schizophrenia spectrum psychotic disorder. Compounds and compositions containing such compounds, and methods of using such compound and compositions are described herein.

Abstract translation: 该应用涉及对α7亚型选择性的α-神经元烟碱受体激动剂，其可用于改善患有精神分裂症，精神分裂症或相关精神分裂症光谱精神病的患者的认知障碍。 包含这些化合物的化合物和组合物以及使用这种化合物和组合物的方法在本文中描述。

公开(公告)号：US20130096132A1

公开(公告)日：2013-04-18

申请号：US13653192

申请日：2012-10-16

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Diana L. Nersesian ,  Kevin B. Sippy ,  Jianguo Ji ,  Tao Li ,  Marc Scanio ,  Lei Shi ,  Chih-Hung Lee ,  William H. Bunnelle ,  Geoff G.Z. Zhang ,  Paul J. Brackemeyer ,  Shuang Chen ,  Rodger F. Henry

IPC: C07D471/18 ,  A61K45/06 ,  A61K31/501 ,  A61K31/496 ,  A61K31/506 ,  A61K31/497 ,  A61K31/439 ,  A61K31/444

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

公开(公告)号：US20190119200A1

公开(公告)日：2019-04-25

申请号：US16091919

申请日：2017-04-06

Applicant: AbbVie Inc.

Inventor： Lawrence A. Black ,  William H. Bunnelle ,  Da Chen ,  Bruce Clapham ,  David A. Degoey ,  Xiangjun Deng ,  Liqiang Fu ,  Lisa A. Hazelwood ,  Linglong Kong ,  Qingyu Lang ,  Chih-Hung Lee ,  Mingfeng Li ,  Greta L. Lundgaard ,  Meena V. Patel ,  Ruihong Tao ,  Lin Zhang ,  Qingwei Zhang ,  Qiangang Zheng ,  Wei Zhu

IPC: C07C235/34 ,  C07D213/69 ,  C07D321/10 ,  C07D307/86 ,  C07D317/46 ,  C07D333/24 ,  C07C323/52 ,  C07F9/38 ,  C07C313/04 ,  C07D209/20 ,  C07C311/32 ,  C07D305/06 ,  C07D213/71 ,  C07C311/51 ,  C07D239/72 ,  C07D239/52 ,  C07D257/06 ,  C07D215/50 ,  C07D217/26 ,  C07D498/04 ,  C07D307/33

Abstract: Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20130165479A1

公开(公告)日：2013-06-27

申请号：US13706468

申请日：2012-12-06

Applicant: AbbVie, Inc.

Inventor： Arthur R. Gomtsyan ,  Robert G. Schmidt, JR. ,  Jerome F. Daanen ,  Erol K. Bayburt ,  Chih-Hung Lee ,  Steven P. Latshaw

IPC: C07C275/26 ,  C07D311/04 ,  C07D215/22

CPC classification number: C07C275/32 ,  C07D215/12 ,  C07D215/42 ,  C07D215/54 ,  C07D311/58 ,  C07D311/74

Abstract: The present application is directed to compounds that are TRPV1 antagonictc and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

Abstract translation: 本申请涉及TRPV1拮抗剂并具有式（I）的化合物，其中变量Ar1，L1，R1，R2，R3，R4，R5，Y1，Y2和Y3如说明书中所定义，它们是有用的 用于治疗由香草素受体活性引起或加剧的病症。